- Home
- DSY vs HOWL Comparison
DSY vs HOWL Comparison
Compare DSY & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- HOWL
- Stock Information
- Founded
- DSY 2020
- HOWL 2017
- Country
- DSY China
- HOWL United States
- Employees
- DSY N/A
- HOWL N/A
- Industry
- DSY
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- HOWL Health Care
- Exchange
- DSY Nasdaq
- HOWL Nasdaq
- Market Cap
- DSY 57.6M
- HOWL 64.5M
- IPO Year
- DSY N/A
- HOWL 2021
- Fundamental
- Price
- DSY $1.40
- HOWL $1.40
- Analyst Decision
- DSY
- HOWL Strong Buy
- Analyst Count
- DSY 0
- HOWL 5
- Target Price
- DSY N/A
- HOWL $7.20
- AVG Volume (30 Days)
- DSY 4.0M
- HOWL 151.8K
- Earning Date
- DSY 01-01-0001
- HOWL 11-06-2025
- Dividend Yield
- DSY N/A
- HOWL N/A
- EPS Growth
- DSY 120.37
- HOWL N/A
- EPS
- DSY 0.01
- HOWL N/A
- Revenue
- DSY $7,323,356.00
- HOWL N/A
- Revenue This Year
- DSY N/A
- HOWL N/A
- Revenue Next Year
- DSY N/A
- HOWL N/A
- P/E Ratio
- DSY $125.80
- HOWL N/A
- Revenue Growth
- DSY 16.37
- HOWL N/A
- 52 Week Low
- DSY $0.95
- HOWL $0.60
- 52 Week High
- DSY $7.33
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- DSY 50.74
- HOWL 56.16
- Support Level
- DSY $1.51
- HOWL $1.38
- Resistance Level
- DSY $7.33
- HOWL $1.49
- Average True Range (ATR)
- DSY 0.50
- HOWL 0.07
- MACD
- DSY 0.03
- HOWL 0.00
- Stochastic Oscillator
- DSY 6.61
- HOWL 55.00
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.